Ağır psikiyatrik bozukluklar, depresyon ve sigara bırakma

Son yıllarda ülkemizde sigarayı bırakma konusunda çok ciddi kampanyalar düzenlenmekte, sağlık çalışanları bu konuda bilinçlendirilmekte ve devlet eliyle bu alana özel tedavi hizmetleri verilmektedir. Ancak ciddi psikiyatrik bozukluğu olanlar arasında sigara içme çok yaygın olmasına ve ciddi bir mortalite ve morbidite nedeni olmasına rağmen psikiyatri uzmanları, psikiyatri hastalarında sigarayı bıraktırma konusunda çok gayretli davranmamakta- dır. Oysa son yıllarda yapılan tedavi çalışmaları göstermiştir ki, ciddi psikiyatrik bozukluğu olan ve klasik bilgilere göre sigarayı bırakmaları çok zor olarak görülen kişilerde de sigarayı bırakma tedavilerinin bazı değişiklikler yapı- larak uygulanmasıyla başarılı sonuçlar alınabilmektedir. Son yıllarda sigarayı bırakma amaçlı ilaç tedavilerinde de gelişmeler olmuştur. Ancak bu alanda kullanılan ilaçların ciddi nöropsikiyatrik yan etkileri olabilmektedir. Her hastada yarar ve risk dengesi gözetilerek uygun tedavi seçeneğinin belirlenmesi gereklidir.

Severe mental disorders, depression and smoking cessation

In recent years, large campaigns have been organized for smoking cessation, health professionals have been educated about this topic and special treatment programs have been developed by the government for smokers. Although cigarette smoking is very frequent among patients with severe mental illness and its a cause of morbi- dity and mortality, psychiatrists are not very eager for smoking cessation among psychiatric patients. However, in recent years, treatment studies have shown that with some modifications, conventional smoking cessation ap- proaches may be quite beneficial among these severe mentally ill patients who are classically known to be fail- ures in such treatments. In recent years, there have been developments in pharmacological approaches for smoking cessation, but neuropsychiatric side effects of these medications may be serious. Risk and benefit ratio for each patient should be taken into account while making a treatment plan.

PDF

___

1. World Health Organization. Guidelines for Cont-rolling and Monitoring the Tobacco Epidemic. Geneva, WHO, 1988.
2. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006; 3:1-14.
3. McClave AK, McKnight-Eily LR, Davis SP, Dube SR. Smoking characteristics of adults with se-lected lifetime mental ıllnesses: results from the 2007 National Health Interview Survey. Am J Public Health 2010; 100:2464-2472.
4. Üçok A, Polat A, Bozkurt O, Meteris H. Cigarette smoking among patients with schizophrenia and bipolar disorders. Psychiatry Clin Neurosci 2004; 58:434-437.
5. Sagud M, Mihaljević-Peles A, Mück-Seler D, Pivac N, Vuksan-Cusa B, Brataljenović T, et al. Smoking and schizophrenia. Psychiatr Danub 2009; 21:371-375.
6. Levin ED, Wilson W, Rose JE, McEvoy J. Nico-tine-haloperidol interactions and cognitive per-formance in schizophrenics. Neuropsychophar-macology 1996; 15:429-436.
7. Barr AM, Prochyshyn RM, Hui P, Johnson JL, Honer WG. Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. Schizophr Res 2008; 100:252-260.
8. Jaimee L Heffner JL, Strawn JR, DelBello MP, Strakowski SM, Anthenelli RM. The co-occur-rence of cigarette smoking and bipolar disorder: phenomenology and treatment considerations. Bipolar Disorders 2011, 13:439-453.
9. Ostacher MJ, Nierenberg AA, Perlis RH, Eidel-man P, Borrelli DJ, Tran TB, et al. The relation-ship between smoking and suicidal behavior, comorbidity, and course of illness in bipolar dis-order. J Clin Psychiatry 2006; 67:1907-1911.
10. Wilens TE, Biederman J, Adamson JJ, Henin A, Sgambati S, Gignac M, et al. Further evidence of an association between adolescent bipolar disor-der with smoking and substance use disorders: a controlled study. Drug Alc Depend 2008; 95:188-198.
11. Diaz FJ, James D, Botts S, Maw L, Susce MT, De Leon J. Tobacco smoking behaviors in bi-polar disorder: a comparison of the general population, schizophrenia, and major depression. Bipolar Disord 2009; 11:154-165.
12. Mineur YS, Picciotto MR. Biological basis for the co-morbidity between smoking and mood disor-ders. J Dual Diagn 2009; 5:122-130.
13. Balfour DJK, Ridley DL. The effects of nicotine on neural pathways implicated in depression: a factor in nicotine addiction? Pharmacol Biochem Behav 2000; 66:79-85.
14. McEachin RC, Saccone NL, Saccone SF, Kley-man-Smith YD, Kar T, Kare RK, et al. Modeling complex genetic and environmental influences on comorbid bipolar disorder with tobacco use disorder. BMC Med Genet 2010; 11:14.
15. Saccone KA, George TP, Head CA, Vessichio JC, Easton CJ, Prigerson HG. Adverse childhood experiences, smoking and mental illness in adult-hood: a preliminary study. Ann Clin Psychiatry 2007; 19:89-97.
16. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: A population-based prevalence study. JAMA 2000; 284:2606-2610.
17. Substance Abuse and Mental Health Services Administration. Results from the 2006 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-32, DHHS Publication No. SMA 07-4293), Rockville, MD, 2007.
18. Ischaki E, Gratziou C. Smoking and depression: Is smoking cessation effective? Ther Adv Respir Dis 2009; 3:31-38.
19. Amerikan Psikiyatri Birliği. Psikiyatride Hastalık-ların Tanımlanması ve Sınıflandırılması El Kitabı. Yeniden gözden geçirilmiş dördüncü baskı (DSM-IV-TR), Washington, DC, Amerikan Psiki-yatri Birliği, E Köroğlu (Çev.), Ankara, Hekimler Yayın Birliği, 2001.
20. Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, et al. Smoking, smoking ces-sation, and major depression. JAMA 1990; 264:1546-1549.
21. Gierisch JM, Bastian LA, Calhoun PS, McDuffie JR, Williams JW. Comparative Effectiveness of Smoking Cessation Treatments for Patients With Depression: A Systematic Review and Meta-analysis of the Evidence. Washington (DC), Department of Veterans Affairs, 2010.
22. Hitsman B, Borrelli B, McChargue DE, Spring B, Niaura R. History of depression and smoking cessation outcome: a meta-analysis. J Consult Clin Psychol 2003; 71:657-663.
23. Siru R, Hulse GK, Tait RJ. Assessing motivation to quit smoking in people with mental illness: a review. Addiction 2009; 104:719-733.
24. Prochaska JJ, Rossi JS, Redding CA, Rosen AB, Tsoh JY, Humfleet GL, et al. Depressed smokers and stage of change: implications for treatment interventions. Drug Alcohol Depend 2004; 76:143-151.
25. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm 2007; 64:1917-1921.
26. Selby P, Voci SC, Zawertailo LA, George TP, Brands B. Individualized smoking cessation treat-ment in an outpatient setting: Predictors of out-come in a sample with psychiatric and addictions co-morbidity. Addict Behav 2010; 35:811-817.
27. Banham L, Gilbody S. Smoking cessation in sev-ere mental illness: what works? Addiction 2010; 105:1176-1189.
28. Moss TG, Weinberger AH, Vessicchio JC, Man-cuso V, Cushing SJ, Pett M, et al. A Tobacco Reconceptualization in Psychiatry (TRIP): to-wards the development of tobacco-free psychi-atric facilities. Am J Addict 2010; 19:293-311.
29. Hitsman B, Moss TG, Montoya ID, George TP. Treatment of tobacco dependence in mental health and addictive disorders. Can J Psychiatry 2009; 54:368-378.
30. Olivier D, Lubman DI, Fraser R. Tobacco smok-ing within psychiatric inpatient settings: bio-psychosocial perspective. Aust N Z J Psychiatry 2007; 41:572-580.
31. Hays JT, Ebbert JO. Adverse effects and tolera-bility of medications for the treatment of tobacco use and dependence. Drugs 2010; 70:2357-2372.
32. George TP, Vessicchio JC, Sacco KA, Weinber-ger AH, Dudas MM, Allen TM et al. A placebo-controlled trial of bupropion combined with nico-tine patch for smoking cessation in schizo-phrenia. Biol Psychiatry 2008; 63:1092-1096.
33. Weiner E, Ball MP, Summerfelt A, Gold J, Buchanan RW. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizo-phrenia. Am J Psychiatry 2001; 158:635-637.
34. Torrens M, Fonseca F, Mateu G, Farre M. Effica-cy of antidepressants in substance use disorders with and without comorbid depression: a syste-matic review and meta-analysis. Drug Alcohol Depend 2005; 78:1-22.
35. Williams JM, Steinberg MB, Steinberg ML, Gandhi KK, Ulpe R, Foulds J. Varenicline for tobacco dependence: panacea or plight? Expert Opin Pharmacother 2011; 12:1799-812.
36. Dutra SJ, Stoeckel LE, Carlini SV, Pizzagalli DA, Evins AE. Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity. Psychopharmacology (Berl) 2012; 219:25-34.
37. Steinberg ML, Ziedonis DM, Krejci J, Brandon TH. Motivational interviewing with personalized feedback: a brief intervention for motivating smokers with schizophrenia to seek treatment for tobacco dependence. J Consult Clin Psychol 2004; 77:723-728.
38. Haas AL, Muñoz RF, Humfleet GL, Reus VI, Hall SM. Influences of mood, depression history, and treatment modality on outcomes in smoking ces-sation. J Consult Clin Psychol 2004; 72:563-570.
39. Hall SM, Tsoh JY, Prochaska JJ, Eisendrath S, Rossi JS, Redding CA, et al. Treatment for cigarette smoking among depressed mental health outpatients: a randomized clinical trial. Am J Public Health 2006; 96:1808-1814.
40. Burton SM, Tiffany ST. The effect of alcohol consumption on craving to smoke. Addiction 1997; 92:15-26.
41. Hall SM, Prochaska JJ. Treatment of smokers with co-occurring disorders: Emphasis on integ-ration in mental health and addiction treatment settings. Annu Rev Clin Psychol 2009; 5:409-431.